Factors Associated With a Patient’s Decision to Select a Cost-effective vs the Most Effective Therapy for Their Own Eye Disease | Zendy

Danyal Malik | Zendy; Xuan Cao | Zendy; Jaron Castillo Sanchez | Zendy; Tianshun Gao | Zendy; Jiang Qian | Zendy; Silvia Montaner | Zendy; Akrit Sodhi | Zendy

Open Access

Factors Associated With a Patient’s Decision to Select a Cost-effective vs the Most Effective Therapy for Their Own Eye Disease

Author(s) -

Danyal Malik,

Xuan Cao,

Jaron Castillo Sanchez,

Tianshun Gao,

Jiang Qian,

Silvia Montaner,

Akrit Sodhi

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.37880

Subject(s) - medicine , bevacizumab , aflibercept , disease , adverse effect , referral , ranibizumab , retrospective cohort study , intensive care medicine , clinical trial , emergency medicine , family medicine , chemotherapy

Key Points Question What factors are associated with a patient’s choice between cost-effective and the most effective medicines for their own health care? Findings In this cohort study of 189 patients with eye diseases, 100 selected a potentially less effective but also less costly drug for the treatment of their eye disease. A surrogate marker for altruism was the strongest factor associated with this decision. Meaning These findings suggest that clinicians should consider the ethical implications of involving patients in selecting their own therapy if altruism is a key driver for this decision.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research